Alane Izu to Vaccines
This is a "connection" page, showing publications Alane Izu has written about Vaccines.
Connection Strength
1,490
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,739
-
Obstetric and neonatal outcomes in South Africa. Vaccine. 2024 Feb 27; 42(6):1352-1362.
Score: 0,202
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
Score: 0,193
-
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. AIDS. 2023 01 01; 37(1):105-112.
Score: 0,185
-
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply. N Engl J Med. 2021 08 05; 385(6):571-572.
Score: 0,170